We are live on ! Find out more
WINT

Windtree Therapeutics
WINT

Delisted

WINT was delisted on the 20th of August, 2025.

Back to rankings

11 hedge funds and large institutions have $521K invested in Windtree Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

10% more funds holding

Funds holding: 10 → 11 (+1)

0% less ownership

Funds ownership: 0% → 0% (-0%)

22% less capital invested

Capital invested by funds: $666K → $521K (-$146K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
11
Holders Change
+1
Holders Change %
+10%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
–
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$35.7K
2
VF
Virtu Financial
New York
+$35.7K
3
Osaic Holdings
Osaic Holdings
Arizona
+$17.9K
4
TSS
Two Sigma Securities
New York
+$17.9K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$53.6K
2
Millennium Management
Millennium Management
New York
-$35.7K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$35K
4
Renaissance Technologies
Renaissance Technologies
New York
-$17.9K
5
TRCT
Tower Research Capital (TRC)
New York
-$17.9K

WINT Hedge Fund Activity: Q3 2022 in Review

11 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q3 2022, worth a combined $521K — down 22% from $666K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new WINT positions and 4 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Envestnet Asset Management, opening a new position worth an estimated $35.7K. The largest seller was Vanguard Group, cutting an estimated $53.6K.

  • 11 institutional investors held Windtree Therapeutics (WINT) as of Q3 2022, up from 10 in Q2 2022.
  • Funds reported $521K of Windtree Therapeutics stock for Q3 2022, down 22% quarter-over-quarter.
  • 5 funds opened new Windtree Therapeutics positions in Q3 2022 and 4 closed out, a net change of +1 holder.
  • The largest Windtree Therapeutics buyer in Q3 2022 was Envestnet Asset Management, an estimated $35.7K added.
  • The largest Windtree Therapeutics seller in Q3 2022 was Vanguard Group, an estimated $53.6K sold.

Based on aggregated 13F filings for Q3 2022.